BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-04
174 industry Phase 2/3 trial readout(s) and 33 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-04 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04785196 APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Liposarcoma; Advanced Solid Tumor | recruiting | 95 |
| 2026-04 est. | P2 | Scientific Center for Anti-infectious Drugs, Kazakhstan | NCT05060705 "Efesovir" (FS-1) for COVID-19, Phase 2 | Covid19 | not yet recruiting | 62 |
| 2026-04 est. | P2 | aTyr Pharma, Inc. ATYR | NCT05892614 Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-I | Interstitial Lung Disease | recruiting | 25 |
| 2026-04 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT06182969 A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | SLE | recruiting | 40 |
| 2026-04 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06199973 Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinot | Advanced Colorectal Cancer | active not recruiting | 130 |
| 2026-04 est. | P3 | Insud Pharma | NCT06282315 Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness | Soil-Transmitted Helminths | recruiting | 20000 |
| 2026-04 est. | P1/P2 | Akeso | NCT06387420 A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | ACUTE MYELOID LEUKEMIA; AML | not yet recruiting | 180 |
| 2026-04 est. | P2/P3 | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | NCT06603142 Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia | Primary Gout; Hyperuricemia | unknown | 636 |
| 2026-04 est. | P3 | JW Pharmaceutical | NCT06643130 Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia | Hypertension; Dyslipidemia | recruiting | 162 |
| 2026-04 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06649214 A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia | Schizophrenia | unknown | 654 |
| 2026-04 est. | P2 | Odyssey Therapeutics, Inc. ODTX | NCT06850727 Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis (UC); UC - Ulcerative Colitis | recruiting | 57 |
| 2026-04 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06925581 A Trial of HRS-6768 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 84 |
| 2026-04 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06947226 A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | Solid Tumors | not yet recruiting | 188 |
| 2026-04 est. | P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT06975748 A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis | Neurotrophic Keratitis | recruiting | 48 |
| 2026-04 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07007936 Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia | Postoperative Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee | not yet recruiting | 90 |
| 2026-04 est. | P3 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT07010107 A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. | Reflux Esophagitis (RE) | recruiting | 500 |
| 2026-04 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07036172 Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients | Obesity Control | recruiting | 460 |
| 2026-04 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07174115 A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps | Chronic Sinusitis Without Nasal Polyps | recruiting | 30 |
| 2026-04 est. | P2 | Alixer Nexgen Therapeutics Limited | NCT07219849 A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure | Seasonal Allergic Rhinitis (SAR) | recruiting | 164 |
| 2026-04-01 est. | P1/P2 | Curis, Inc. CRIS | NCT04278768 Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia; Myelodysplastic Syndrome | suspended | 366 |
| 2026-04-01 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04342910 Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | Gastric Cancer | recruiting | 550 |
| 2026-04-01 | P1/P2 | ModernaTX, Inc. | NCT04899310 A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia | Methylmalonic Acidemia | terminated | 18 |
| 2026-04-01 | P2/P3 | Insmed Incorporated INSM | NCT05649722 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension; Interstitial Lung Disease | completed | 31 |
| 2026-04-01 | P1/P2 | Praxis Precision Medicines PRAX | NCT05737784 A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy | SCN2A-DEE; Epilepsy | active not recruiting | 60 |
| 2026-04-01 est. | P3 | Protagonist Therapeutics, Inc. PTGX | NCT06033586 Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | Polycythemia Vera | active not recruiting | 46 |
| 2026-04-01 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06079983 JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Breast Cancer | recruiting | 400 |
| 2026-04-01 | P3 | Janssen Research & Development, LLC | NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and | Multiple Myeloma | active not recruiting | 838 |
| 2026-04-01 | P1/P2 | Theradaptive, Inc | NCT07078331 Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations | Tooth Extraction Site Healing; Ridge Augmentation; Bone Graft | active not recruiting | 45 |
| 2026-04-01 est. | P1/P2 | ExoRNA Bioscience | NCT07339514 A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. | Huntington Disease | active not recruiting | 27 |
| 2026-04-01 | P3 | Newsoara Biopharma Co., Ltd. | NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis | Psoriasis | completed | 607 |
| 2026-04-02 | P3 | Immunovant Sciences GmbH IMVT | NCT05517447 Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease | Thyroid Eye Disease | terminated | 109 |
| 2026-04-02 | P2 | Bial R&D Investments, S.A. | NCT05819359 Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | Parkinson's Disease | completed | 273 |
| 2026-04-02 | P1/P2 | iOmx Therapeutics AG | NCT05826600 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Solid Tumor | terminated | 68 |
| 2026-04-02 | P3 | Oculis OCS | NCT06172257 A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) | Diabetic Macular Edema | completed | 401 |
| 2026-04-02 | P2 | Merck Sharp & Dohme LLC MRK | NCT06956235 Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) | Hidradenitis Suppurativa | active not recruiting | 149 |
| 2026-04-02 | P2 | RDC Clinical Pty Ltd | NCT07412730 Glucose Tolerance Study | Healthy Volunteers; Glucose Tolerance | completed | 19 |
| 2026-04-02 | P2 | Joincare Pharmaceutical Group Industry Co., Ltd | NCT07440524 A Phase 2 Trial of JKN24011 in COPD | COPD (Chronic Obstructive Pulmonary Disease) | completed | 215 |
| 2026-04-03 | P3 | Arog Pharmaceuticals, Inc. | NCT03250338 Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | completed | 106 |
| 2026-04-03 | P3 | RemeGen Co., Ltd. | NCT03330418 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders | Neuromyelitis Optica Spectrum Disorders | terminated | 178 |
| 2026-04-03 | P2 | RemeGen Co., Ltd. | NCT04625153 RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial | Multiple Sclerosis, Relapsing-Remitting | terminated | 8 |
| 2026-04-03 | P1/P2 | Sanofi SNY | NCT06695130 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Inf | COVID-19 Immunization; Influenza Immunization | completed | 980 |
| 2026-04-03 | P3 | Ondine Biomedical Inc. | NCT06702878 Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Surgical Site Infections; Surgical Wound Infection; Infections; Anti-Infective Agents | completed | 4787 |
| 2026-04-03 | P3 | AbbVie ABBV | NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult P | Forehead Lines | completed | 150 |
| 2026-04-05 | P2 | Lisata Therapeutics, Inc. LSTA | NCT05712356 A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Extr | completed | 66 |
| 2026-04-06 | P3 | Arog Pharmaceuticals, Inc. | NCT03258931 Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | Newly Diagnosed FLT3 Mutated AML | completed | 214 |
| 2026-04-06 | P3 | Eli Lilly and Company LLY | NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea | completed | 2335 |
| 2026-04-06 | P2 | CalciMedica, Inc. CALC | NCT06374797 A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" | Acute Kidney Injury | terminated | 122 |
| 2026-04-06 | P3 | Alcon Research ALC | NCT07082816 Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension; Open Angle Glaucoma | completed | 489 |
| 2026-04-07 | P2 | Evaxion Biotech A/S EVAX | NCT05309421 A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | Melanoma Stage IV; Unresectable Melanoma | completed | 17 |
| 2026-04-07 | P3 | Gan & Lee Pharmaceuticals. | NCT07527078 Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes | Type 2 Diabetes (T2DM) | recruiting | 350 |
| 2026-04-08 | P2 | photonamic GmbH & Co. KG | NCT03897491 PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | Glioblastoma | terminated | 17 |
| 2026-04-08 est. | P1/P2 | Celgene | NCT04882163 Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B- | Lymphoma, B-Cell | withdrawn | |
| 2026-04-08 | P3 | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | NCT07028801 Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) | Rabies | completed | 3000 |
| 2026-04-09 | P3 | UCB Biopharma SRL | NCT04123795 A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis | Moderate Chronic Plaque Psoriasis; Severe Chronic Plaque Psoriasis; Mixed Guttate/Plaque Psoriasis | completed | 49 |
| 2026-04-09 | P1/P2 | Cantargia AB | NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | Triple Negative Breast Cancer | completed | 117 |
| 2026-04-09 | P2 | Merck Sharp & Dohme LLC MRK | NCT05612035 Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | active not recruiting | 129 |
| 2026-04-09 | P1/P2 | Pfizer PFE | NCT05896163 A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory | Diffuse Large B-Cell Lymphoma | terminated | 40 |
| 2026-04-09 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06792136 A Study of ONO-1110 in Patients With Major Depressive Disorder | Major Depressive Disorder (MDD | completed | 103 |
| 2026-04-09 | P3 | AgelessRx | NCT07475546 Combination Gerotherapeutic Interventions for Healthspan Improvement | Healthspan Improvement; Aging; Longevity | completed | 26 |
| 2026-04-09 | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07814651 A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly | Acromegaly | completed | 78 |
| 2026-04-10 | P2/P3 | Oculis OCS | NCT05066997 A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) | Diabetic Macular Edema | completed | 552 |
| 2026-04-10 | P3 | PharmaMar | NCT05153239 Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cance | Relapsed Small Cell Lung Cancer | completed | 705 |
| 2026-04-10 | P3 | Anthos Therapeutics, Inc. | NCT05171075 A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE | Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism | terminated | 417 |
| 2026-04-10 | P2 | ITB-Med LLC | NCT05669001 A Study of TCD601 in de Novo Renal Transplant Recipients | Renal Transplantation | completed | 76 |
| 2026-04-10 | P2 | Reistone Biopharma Company Limited | NCT07158151 A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis | Atopic Dermatitis of Adults | completed | 168 |
| 2026-04-10 | P2 | Sichuan Purity Pharmaceutical Technology Co., Ltd. | NCT07193901 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Su | Major Depressive Disorder (MDD | completed | 98 |
| 2026-04-10 | P3 | R-Pharm International, LLC | NCT07670546 Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) | Polymyalgia Rheumatica | active not recruiting | 125 |
| 2026-04-11 | P3 | Novartis Pharmaceuticals NVS | NCT04889430 Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy | Atypical Hemolytic Uremic Syndrome | completed | 34 |
| 2026-04-13 | P2 | Takeda TAK | NCT02615184 A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old | Erosive Esophagitis | terminated | 24 |
| 2026-04-13 | P3 | Chiesi Farmaceutici S.p.A. | NCT03614234 Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients | Fabry Disease | completed | 29 |
| 2026-04-13 | P3 | Celgene | NCT03651128 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | completed | 386 |
| 2026-04-13 | P1/P2 | Janssen Pharmaceutical K.K. | NCT04696809 A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Hematologic Malignancies | completed | 40 |
| 2026-04-13 | P2 | Shaperon | NCT06024499 Phase 2 Trial of HY209gel in Atopic Dermatitis Patients | Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis of Scalp | completed | 210 |
| 2026-04-14 | P3 | Tanabe Pharma America, Inc. | NCT06144840 INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | completed | 165 |
| 2026-04-14 | P2 | Omeros Corporation OMER | NCT06209736 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis | terminated | 3 |
| 2026-04-14 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06492941 A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer | Advanced Pancreatic Cancer | not yet recruiting | 142 |
| 2026-04-14 | P2 | LimmaTech Biologics AG | NCT06615375 A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine | Shigellosis | completed | 97 |
| 2026-04-14 | P3 | Inventera Inc. | NCT07057037 Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases | Rotator Cuff Tear; Labral Tear; Rotator Cuff Tendinosis; Rotator Cuff Tendonitis; Articular Cartilag | completed | 85 |
| 2026-04-14 | P2 | Reinovax Biologics Co., LTD | NCT07333352 PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months | Pneumococcal Infectious Disease | completed | 480 |
| 2026-04-15 | P3 | ViiV Healthcare | NCT05979311 A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Trea | HIV; HIV Infections | active not recruiting | 463 |
| 2026-04-15 | P1/P2 | Respirion Pharmaceuticals Pty Ltd | NCT06016088 A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection | Cystic Fibrosis Lung; Respiratory Infections, Recurrent, Chronic; Pseudomonas Aeruginosa | completed | 71 |
| 2026-04-15 est. | P1/P2 | Shanghai Refreshgene Technology Co., Ltd. | NCT06141460 Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | recruiting | 48 |
| 2026-04-15 | P2 | PRInnovation GmbH | NCT06182085 Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease, Early Onset | completed | 304 |
| 2026-04-15 | P2 | ZYUS Life Sciences Inc. | NCT06533657 Unique Treatment of Oncology Pain in Advanced Cancer | Cancer Pain | completed | 11 |
| 2026-04-15 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06897579 Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Seque | Extensive Stage Small Cell Lung Cancer | terminated | 40 |
| 2026-04-15 | P3 | Aardvark Therapeutics, Inc. AARD | NCT07197034 The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial | Hyperphagia; Prader-Willi Syndrome; Hyperphagia in Prader-Willi Syndrome | terminated | 19 |
| 2026-04-15 | P2 | Desentum Oy | NCT07254871 Study of DM-101PX in Adults With Birch Pollen Allergy | Birch Pollen Allergy | completed | 97 |
| 2026-04-15 | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT07259564 A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) | Adult Growth Hormone Deficiency (AGHD) | terminated | 120 |
| 2026-04-16 | P2 | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | NCT05270668 Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7 | Diffuse Cutaneous Systemic Sclerosis; Interstitial Lung Disease | active not recruiting | 154 |
| 2026-04-16 | P2 | Takeda TAK | NCT05714969 A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) | Thrombotic Thrombocytopenic Purpura (TTP) | completed | 29 |
| 2026-04-16 | P3 | Eli Lilly and Company LLY | NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Obesity; Cardiovascular Diseases | completed | 1946 |
| 2026-04-16 | P3 | HTA Co., Ltd. | NCT06011304 Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer | Prostate Cancer | completed | 287 |
| 2026-04-16 | P3 | Celltrion | NCT06571591 Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin | T2DM | completed | 606 |
| 2026-04-16 | P1/P2 | Sanofi SNY | NCT06695117 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inact | COVID-19 Immunization; Influenza Immunization | completed | 980 |
| 2026-04-16 | P2 | Salubris Biotherapeutics Inc | NCT07221513 Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension | HFrEF - Heart Failure With Reduced Ejection Fraction; HFpEF - Heart Failure With Preserved Ejection | withdrawn | |
| 2026-04-17 | P3 | Baxalta now part of Shire | NCT02932618 A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) | Von Willebrand Disease | completed | 47 |
| 2026-04-17 | P3 | AbbVie ABBV | NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkins | Parkinson's Disease (PD) | completed | 130 |
| 2026-04-17 | P3 | AstraZeneca AZN | NCT06502366 A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA | Asthma | completed | 424 |
| 2026-04-17 | P3 | Amgen AMGN | NCT06527404 A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis | Prurigo Nodularis | terminated | 469 |
| 2026-04-17 | P3 | Gilead Sciences GILD | NCT06630286 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV- | HIV-1-infection | active not recruiting | 609 |
| 2026-04-17 | P3 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | NCT06890533 A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery | Pain | active not recruiting | 560 |
| 2026-04-17 | P3 | Shandong Suncadia Medicine Co., Ltd. | NCT06904105 A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity | Overweight; Obesity | completed | 556 |
| 2026-04-18 est. | P1/P2 | Novadip Biosciences | NCT05961956 Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis | Degenerative Lumbar Spondylolisthesis | active not recruiting | 5 |
| 2026-04-18 | P2 | MBX Biosciences MBX | NCT07029412 Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) | Postbariatric Hypoglycemia | completed | 20 |
| 2026-04-18 | P3 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT07275723 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central | For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions | completed | 309 |
| 2026-04-20 | P1/P2 | BioMarin Pharmaceutical BMRN | NCT04684940 Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | Hemophilia A With Inhibitor; Hemophilia A With Anti Factor VIII | completed | 10 |
| 2026-04-20 | P1/P2 | Elicio Therapeutics ELTX | NCT05726864 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D; KRAS G12R; KRAS G12V; KRAS G12A; KRA | active not recruiting | 158 |
| 2026-04-20 | P1/P2 | Akeso | NCT06586294 A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Loc | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | completed | 35 |
| 2026-04-20 | P2 | BeBetter Med Inc | NCT06685796 A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer | Advanced Triple-Negative Breast Cancer | completed | 65 |
| 2026-04-20 est. | P3 | Beijing VDJBio Co., LTD. | NCT06726096 Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis | Rheumatoid Arthritis (RA); Anti IL-6R | enrolling by invitation | 615 |
| 2026-04-20 | P2 | Beijing Keymed Biosciences Co., Ltd. | NCT06930612 A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1) | Chronic Rhinosinusitis With Nasal Polyposis | completed | 120 |
| 2026-04-20 | P1/P2 | Accro Bioscience (Suzhou) Limited | NCT07083193 A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis | completed | 25 |
| 2026-04-20 est. | P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT07123402 To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia | Chronic Postoperative Neuralgia | enrolling by invitation | 184 |
| 2026-04-21 | P2 | Hutchison Medipharma Limited | NCT04923932 Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | Gastric Cancer; Esophagogastric Junction Disorder | completed | 110 |
| 2026-04-21 | P3 | Novo Nordisk A/S NVO | NCT05135559 A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors | Haemophilia A and B With and Without Inhibitors | active not recruiting | 153 |
| 2026-04-21 | P2 | Merck Sharp & Dohme LLC MRK | NCT05144841 A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | 140 |
| 2026-04-21 | P3 | Lantheus Germany GmbH LNTH | NCT05184088 Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | Cardiac Amyloidosis; AL Amyloidosis; ATTR Amyloidosis | completed | 244 |
| 2026-04-21 | P3 | Hansa Biopharma AB | NCT05369975 Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts | Kidney Transplantation in Highly Sensitized Patients | completed | 113 |
| 2026-04-21 | P1/P2 | Vertex Pharmaceuticals Incorporated VERX | NCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Cystic Fibrosis | completed | 26 |
| 2026-04-21 | P3 | VistaGen Therapeutics, Inc. VTGN | NCT06615557 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Social Anxiety Disorder (SAD) | completed | 238 |
| 2026-04-21 | P2 | AstraZeneca AZN | NCT06897748 A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary | Chronic Obstructive Pulmonary Disease (COPD) | completed | 98 |
| 2026-04-21 | P3 | Sandoz | NCT07223294 Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg | Respiratory | withdrawn | |
| 2026-04-21 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07233655 A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis | Moderate to Severe Active Rheumatoid Arthritis | active not recruiting | 30 |
| 2026-04-22 | P3 | Novo Nordisk A/S NVO | NCT06388187 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Obesity | completed | 300 |
| 2026-04-22 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06688123 Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects | Type 2 Diabetes | completed | 275 |
| 2026-04-22 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06812325 A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease (TED) | active not recruiting | 320 |
| 2026-04-22 | P2 | Autobahn Therapeutics, Inc. | NCT06869187 Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Bipolar Disorder Depression | active not recruiting | 35 |
| 2026-04-22 | P3 | Takeda TAK | NCT06973291 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | Plaque Psoriasis | completed | 606 |
| 2026-04-22 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT06973577 P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | ADHD; Anxiety; Generalized Anxiety; Social Anxiety Disorder | completed | 315 |
| 2026-04-23 | P3 | Almirall, S.A. | NCT05916365 Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | completed | 174 |
| 2026-04-23 | P3 | BioMarin Pharmaceutical BMRN | NCT06455059 Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | Hypochondroplasia | completed | 81 |
| 2026-04-23 | P3 | Gilead Sciences GILD | NCT06630299 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | HIV-1-Infection | active not recruiting | 600 |
| 2026-04-23 | P2 | Radiopharm Theranostics, Ltd RADX | NCT06777433 Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases | Brain Metastases From Solid Tumors | active not recruiting | 30 |
| 2026-04-23 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06820749 A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion | Asthma Bronchiale; Bronchiectasis; Chronic Obstructive Pulmonary Disease (COPD) | enrolling by invitation | 309 |
| 2026-04-23 | P1/P2 | Werewolf Therapeutics, Inc. HOWL | NCT06939283 A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | Advanced or Metastatic Solid Tumors; Non-Hodgkin Lymphoma | completed | 24 |
| 2026-04-23 | P2 | Inimmune Corporation | NCT07556393 Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis | Allergic Rhinitis Due to Allergens; Rhinitis Allergic; Allergic Rhinitis | completed | 78 |
| 2026-04-23 | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT07634744 A Phase IIa Study in Primary IgA Nephropathy Patients | IgA Nephropathy | completed | 25 |
| 2026-04-24 | P3 | Merck Sharp & Dohme LLC MRK | NCT04895358 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3 | Breast Neoplasms | active not recruiting | 342 |
| 2026-04-24 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05279313 A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. | Attention Deficit/Hyperactivity Disorder | completed | 680 |
| 2026-04-24 | P3 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06804590 A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis | Postmenopausal Women Osteoporosis | completed | 280 |
| 2026-04-24 | P2 | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | NCT07096791 A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression | Postpartum Depressive Disorder | completed | 72 |
| 2026-04-25 | P2 | ST Pharm Co., Ltd. | NCT05869643 A Clinical Trial of STP0404 in Adults With HIV-1 Infection | HIV-1-infection | completed | 25 |
| 2026-04-25 | P3 | Natureceuticals Sdn Bhd | NCT07669506 A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer U | Breast Neoplasms; Fatigue; Quality of Life; Chemotherapy, Adjuvant | completed | 180 |
| 2026-04-26 est. | P2 | WinSanTor, Inc | NCT05488873 A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy | Chemotherapy-induced Peripheral Neuropathy | unknown | 60 |
| 2026-04-27 | P3 | BeOne Medicines ONC | NCT04002297 A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lym | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | active not recruiting | 510 |
| 2026-04-27 | P3 | AbbVie ABBV | NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkin | Parkinson's Disease (PD) | completed | 118 |
| 2026-04-27 est. | P2 | CNS Pharmaceuticals, Inc. CNSP | NCT04762069 A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | active not recruiting | 252 |
| 2026-04-27 | P2 | Agenus Inc. AGEN | NCT05529316 A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Advanced Melanoma | terminated | 150 |
| 2026-04-27 | P2 | Jemincare | NCT06670534 A Dose-finding Study of JMKX003142 in Treatment of Renal Edema | Edema Secondary; Edema Leg | completed | 133 |
| 2026-04-28 | P3 | Abivax S.A. ABVX | NCT05535946 ABTECT - Maintenance | Ulcerative Colitis | active not recruiting | 1116 |
| 2026-04-28 est. | P2 | Hansoh BioMedical R&D Company | NCT06176508 Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis | Psoriatic Arthritis | unknown | 160 |
| 2026-04-28 | P2 | Amgen AMGN | NCT06312020 A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome | Sjogren's Syndrome | terminated | 209 |
| 2026-04-28 | P2 | Hoffmann-La Roche | NCT07081958 A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity | Obesity or Overweight | completed | 352 |
| 2026-04-28 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07252908 A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder | Pulmonary Disease, Chronic Obstructive | completed | 195 |
| 2026-04-28 | P2 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | NCT07742852 ASKC200 for Knee Osteoarthritis Pain | Osteoarthritis (OA) of the Knee; Pain | active not recruiting | 175 |
| 2026-04-29 | P3 | Cerus Corporation CERS | NCT03037164 INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections | Anemia | completed | 692 |
| 2026-04-29 est. | P3 | Ocular Therapeutix, Inc. OCUL | NCT06223958 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degen | Neovascular Age-Related Macular Degeneration | active not recruiting | 344 |
| 2026-04-29 | P2 | Ribocure Pharmaceuticals AB | NCT06717074 A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease | Stable Coronary Artery Disease CAD | completed | 30 |
| 2026-04-29 | P3 | Colgate Palmolive CL | NCT07398846 Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivi | Plaque | completed | 134 |
| 2026-04-30 | P3 | Hoffmann-La Roche | NCT03274492 A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophos | Diffuse Large B-Cell Lymphoma | completed | 1000 |
| 2026-04-30 | P3 | Zealand Pharma ZEAL.CO | NCT03905707 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS | Short Bowel Syndrome | completed | 150 |
| 2026-04-30 | P3 | Zealand Pharma ZEAL.CO | NCT04881825 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial | Short Bowel Syndrome | completed | 84 |
| 2026-04-30 | P1/P2 | Cantex Pharmaceuticals | NCT05635734 Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | Glioblastoma | completed | 33 |
| 2026-04-30 | P2/P3 | Immutep S.A.S. IMMP | NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy | Breast Carcinoma | terminated | 72 |
| 2026-04-30 est. | P3 | Shenzhen TargetRx Co., Ltd. | NCT06082635 TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | active not recruiting | 321 |
| 2026-04-30 est. | P2 | Oncotherapeutics | NCT06115135 A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory | recruiting | 39 |
| 2026-04-30 est. | P1/P2 | Multitude Therapeutics Inc. | NCT06209580 AMT-253 in Patients With Advanced Solid Tumours | Malignant Melanoma; Advanced Solid Tumors | recruiting | 96 |
| 2026-04-30 | P2 | AstraZeneca AZN | NCT06450197 Phase IIa Study Evaluating AZD7798 in Crohn's Disease | Moderate to Severe Crohn's Disease | active not recruiting | 120 |
| 2026-04-30 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06589778 A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | unknown | 124 |
| 2026-04-30 est. | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06685978 Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands | Hyperplasia of Mammary Glands | recruiting | 430 |
| 2026-04-30 est. | P3 | Wuhan Createrna Science and Technology Co., Ltd | NCT06716970 QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension | Essential Hypertension | not yet recruiting | 810 |
| 2026-04-30 est. | P2 | Tiziana Life Sciences LTD TLSA | NCT06890923 Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | Non-Active Secondary Progressive Multiple Sclerosis | recruiting | 55 |
| 2026-04-30 est. | P2 | Centessa Pharmaceuticals (UK) Limited | NCT07096674 A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | recruiting | 90 |
| 2026-04-30 est. | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT07154342 A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis | Allergic Rhinitis, Seasonal | recruiting | 150 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.